Company intelligence / Profile preview

Xi'an Xinlu Biotechnology

Xi'an, Shaanxi, China

Ownership: Private
Employees: ~201
Development stage: Other

Overview

Xi'an Xinlu Biotechnology produces and supplies active pharmaceutical ingredients (APIs), plant extracts, and intermediates such as matrine, oxymatrine, magnolol, honokiol, and cytisine. Several products are approved by Chinese and European authorities for medicinal use, but the company itself does not sponsor clinical trials.

Modalities: Small moleculeNatural product
Industry: Contract Manufacturing Organization

Beyond the preview

Go deeper on Xi'an Xinlu Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xi'an Xinlu Biotechnology.

Explore the full profile